Reserve Now at FFF: mFLUSIVA®

August 11, 2026

Moderna's mFLUSIVA® — the first mRNA flu vaccine authorized in the U.S. — is now available to reserve on FFF's BioSupply®.

The vaccine was recently approved by the FDA for adults aged 50 and older for the 2026-27 flu season.

View Moderna's mFLUSIVA®

Reserve on BioSupply®

Product Size Manufacturer Prescribing Info
mRNA
mFLUSIVA® 0.38 mL Single-dose Pre-filled Syringe 10 Carton Moderna US, Inc. Link to Full PI

INDICATIONS AND USAGE

mFLUSIVA® is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B represented in the vaccine. mFLUSIVA® is approved for use in persons 50 years of age and older.

The indication for persons 65 years of age and older is approved under accelerated approval based on immune responses. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Let Us Help!

To place an order for mFLUSIVA® or any other Influenza, COVID-19, or RSV product, please reach out to our friendly Wow! Customer Care team at (800) 843-7477 or your FFF Sales Representative. We're here to assist.

Thank you for trusting FFF to serve your patients and communities as you prepare for the upcoming respiratory season.

Your partners in healthcare,

The FFF Enterprises Team